These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 2729882)

  • 1. The protracted effect of o,p'-DDD in Cushing's disease and its impact on adrenal morphogenesis of young human embryo.
    Leiba S; Weinstein R; Shindel B; Lapidot M; Stern E; Levavi H; Rusecki Y; Abramovici A
    Ann Endocrinol (Paris); 1989; 50(1):49-53. PubMed ID: 2729882
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The effects of o,p'-DDD on human adrenal steroid synthesis].
    Ojima M; Saito M; Fukuchi S
    Nihon Naibunpi Gakkai Zasshi; 1984 Jul; 60(7):852-71. PubMed ID: 6094274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma level monitoring of mitotane (o,p'-DDD) and its metabolite (o,p'-DDE) during long-term treatment of Cushing's disease with low doses.
    Benecke R; Keller E; Vetter B; de Zeeuw RA
    Eur J Clin Pharmacol; 1991; 41(3):259-61. PubMed ID: 1748144
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful treatment of Cushing's disease with o,p'-DDD followed by pituitary irradiation in a 19-year-old male patient.
    Dickerman Z; Kaufman H; Laron Z
    Isr J Med Sci; 1979 May; 15(5):455-9. PubMed ID: 447515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. o,p'-DDD (mitotane) treatment for Cushing's syndrome: adrenal drug concentration and inhibition in vitro of steroid synthesis.
    Touitou Y; Moolenaar AJ; Bogdan A; Auzéby A; Luton JP
    Eur J Clin Pharmacol; 1985; 29(4):483-7. PubMed ID: 4092727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The long-term therapy of hypothalamic-hypophyseal Cushing's syndrome with mitotane (o,p'-DDD)].
    Knappe G; Gerl H; Ventz M; Rohde W
    Dtsch Med Wochenschr; 1997 Jul; 122(28-29):882-6. PubMed ID: 9264918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effects of o,p'-DDD on pituitary-gonadal function in patients with Cushing's disease].
    Ojima M; Hashimoto S; Itoh N; Kusano Y; Satoh K; Egawa M; Gomibuchi T; Fukuchi S
    Nihon Naibunpi Gakkai Zasshi; 1988 Jun; 64(6):451-62. PubMed ID: 3145221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of o,p'-DDD on cortisol metabolism in Cushing's syndrome of various etiology.
    Koide Y; Inoue S; Murayama H; Kawai K; Yamashita K
    Endocrinol Jpn; 1985 Oct; 32(5):615-24. PubMed ID: 3004927
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Multiple recurrence of Cushing's syndrome after bilateral adrenalectomy and pituitary gland surgery. Cure with o,p'-DDD].
    Bigler U; Müller J
    Schweiz Med Wochenschr; 1978 Jan; 108(2):67-72. PubMed ID: 622536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [A case of Cushing's disease treated with o,p'-DDD].
    Kaneko K; Saito T; Fujioka T; Sugita Y; Takai K
    Horumon To Rinsho; 1982 Oct; 30(10):1071-6. PubMed ID: 7165981
    [No Abstract]   [Full Text] [Related]  

  • 11. Significant regression of the tumor combined with the high level of plasma cortisol by low-dose administration of O, p'-DDD in a case with Cushing's syndrome caused by adrenocortical carcinoma.
    Otokida K; Nakamura M; Takeda M; Ito T; Kato M; Masuda T; Tashiro A
    Tohoku J Exp Med; 1986 Dec; 150(4):407-15. PubMed ID: 3564003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Treatment of Cushing's disease with o, p'-DDD (author's transl)].
    Nakagawa K; Ito S; Ohara T; Kubo M; Horikawa H
    Horumon To Rinsho; 1981 Sep; 29(9):1135-9. PubMed ID: 7326856
    [No Abstract]   [Full Text] [Related]  

  • 13. Effect of o,p'-DDD on plasma ACTH concentration in Cushing's disease.
    Bruno OD; Hoschoian JC; Andrada JA
    Medicina (B Aires); 1979; 39(2):229-34. PubMed ID: 228150
    [No Abstract]   [Full Text] [Related]  

  • 14. The organochlorine o,p'-DDD disrupts the adrenal steroidogenic signaling pathway in rainbow trout (Oncorhynchus mykiss).
    Lacroix M; Hontela A
    Toxicol Appl Pharmacol; 2003 Aug; 190(3):197-205. PubMed ID: 12902190
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative CYP-dependent binding of the adrenocortical toxicants 3-methylsulfonyl-DDE and o,p'-DDD in Y-1 adrenal cells.
    Hermansson V; Asp V; Bergman A; Bergström U; Brandt I
    Arch Toxicol; 2007 Nov; 81(11):793-801. PubMed ID: 17487473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of Cushing's disease with o,p'-DDD.
    Cooper PR; Shucart WA
    N Engl J Med; 1979 Jul; 301(1):48-9. PubMed ID: 449914
    [No Abstract]   [Full Text] [Related]  

  • 17. [Treatment of Cushing's syndrome and adrenal cancer with O,p-DDD].
    Kinouchi T; Shimizu N; Ibayashi H; Demura H; Oshima H
    Horumon To Rinsho; 1982 Aug; 30(8):841-51. PubMed ID: 7139984
    [No Abstract]   [Full Text] [Related]  

  • 18. Effect of o,p'-DDD on cortisol secretory pattern in Cushing's syndrome.
    Hellman L; Weitzman ED; Roffwarg H; Fukushima DK; Yoshida K; Zumoff B; Gallagher TF
    J Clin Endocrinol Metab; 1970 Aug; 31(2):227-30. PubMed ID: 4316529
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical role of determination of plasma mitotane and its metabolites levels in patients with adrenal cancer: results of a long-term follow-up.
    Kasperlik-Zaluska AA; Cichocki A
    J Exp Ther Oncol; 2005; 5(2):125-32. PubMed ID: 16471038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bovine adrenal cortex transformations of mitotane [1-(2-chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane; o,p'-DDD] and its p,p'- and m,p'-isomers.
    Cai W; Benitez R; Counsell RE; Djanegara T; Schteingart DE; Sinsheimer JE; Wotring LL
    Biochem Pharmacol; 1995 May; 49(10):1483-9. PubMed ID: 7763292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.